Bank of New York Mellon Corp Buys 2,596 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Bank of New York Mellon Corp raised its stake in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 18.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 16,492 shares of the company’s stock after purchasing an additional 2,596 shares during the quarter. Bank of New York Mellon Corp’s holdings in Gyre Therapeutics were worth $127,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Wells Fargo & Company MN raised its holdings in shares of Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after purchasing an additional 913 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after acquiring an additional 1,996 shares in the last quarter. Barclays PLC grew its position in shares of Gyre Therapeutics by 13.5% during the 4th quarter. Barclays PLC now owns 10,543 shares of the company’s stock valued at $128,000 after acquiring an additional 1,255 shares during the period. GAMMA Investing LLC increased its stake in shares of Gyre Therapeutics by 15,083.3% in the 1st quarter. GAMMA Investing LLC now owns 1,822 shares of the company’s stock valued at $140,000 after purchasing an additional 1,810 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Gyre Therapeutics by 9.1% in the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock valued at $1,251,000 after purchasing an additional 8,624 shares in the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Trading Up 1.4%

Shares of GYRE stock opened at $7.02 on Thursday. Gyre Therapeutics, Inc. has a 12-month low of $6.11 and a 12-month high of $19.00. The business’s 50 day moving average is $7.77 and its two-hundred day moving average is $9.30. The company has a market capitalization of $658.20 million, a P/E ratio of 351.18 and a beta of 1.80.

Gyre Therapeutics (NASDAQ:GYRE) last announced its earnings results on Friday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.03. The firm had revenue of $22.06 million for the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a return on equity of 9.73% and a net margin of 7.20%.

Gyre Therapeutics Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.